Earnings call transcript: Clover Corporation’s Q1 2026 sees record revenue

Clover reported record H1 FY2026 revenue of AUD 44.1m (+17.3%), gross margin 35.6% (up 520bps), EBITDA AUD 6.9m (+60.5%) and NPAT AUD 4.2m (+75%); shares jumped ~18.1% post-release. Management declared an interim fully‑franked dividend of AUD 0.01, repaid all bank debt, and ended the half with cash ~AUD 10.3m but a material inventory build (raw materials up materially, inventory +42.5%) that ties up working capital and contributed to lower operating cash flow. Company reiterated FY2026 revenue guidance of AUD 92–96m and provided EPS forecasts of USD 0.87–1.31 through FY2027, highlighted product opportunities (DHA/ARA, Choline‑XL IP pending) while noting an AUD 1.7m FX headwind and competitive/working‑capital risks.

Analysis

Clover’s combination of vertical integration (owned Ecuador crude supply and a New Zealand spray-dry partner) plus a broadened product set creates an outsized optionality on margin capture as specialty oils and powdered derivatives re-price after competitor dislocations. The real second-order beneficiary is the packaged-powder supply chain (specialty packaging, contract spray-dry capacity and shelf-life testing partners) — constrained capacity there will act as a gating factor for revenue conversion, giving Clover pricing leverage in negotiations for at least 6–12 months.

Near-term stretch risks are operational (inventory funding and freight surcharge pass-through lag) and financial (currency translation swings). Inventory accumulation will depress free cash flow for multiple quarters and creates a knock-on risk: if customer qualification cycles slip, the company could face margin compression from forced discounting or higher working-capital financing costs.

Binary catalysts to watch with precise timing are the pending choline IP decision (expected July) and the cadence of ARA customer qualifications through H2–FY27; both can re-rate the stock materially if uptake accelerates. Conversely, a quick competitor remediation (supply-restoration within 3–6 months) or a sharp AUD appreciation would meaningfully reduce upside and could flip sentiment swiftly.

Key Decisions for Investors

• Long CLV (ASX:CLV) equity, size 2–3% NAV. Entry: stagger 50% now, 50% on any pullback ≥10% within 8 weeks. Target: +50–70% out to 12–18 months if H2 conversion and choline IP progress; stop-loss 18% to limit downside from inventory/FX shocks.
• Long CLV 12-month ATM call options (or LEAP equivalent) for leveraged exposure to the July IP decision and FY27 adoption curve. Position size 0.5–1.0% NAV; asymmetric payoff if IP grants and customer trials convert. Time decay is the primary risk—trim into the post-catalyst pop.
• Hedge the equity exposure with short-dated CLV puts (protective put collar) sized to cap downside to ~15% while retaining upside participation. Use puts expiring 3–6 months to cover the inventory/FX risk window; cost can be partially funded by selling slightly OTM calls if comfortable capping upside.